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Abstract
Background Germline mutations in the susceptibility
genes RET, SDHB, SDHD, and VHL have been reported in
7.5–24% of patients with pheochromocytoma (Pheo) or
paraganglioma (PGL) and sporadic presentation. The pur-
pose of the present study was to establish population-based
data on the frequency of germline mutations in patients
with apparently sporadic Pheo or abdominal PGL in
Western Sweden.
Methods From the Swedish National Cancer Registry, all
patients with Pheo or PGL in Western Sweden (population
1.72 million) registered between 1958 and 2009 were
identiﬁed (n = 256). Patients were characterized using
register data, hospital records, and clinical interviews. All
living patients with Pheo or abdominal PGL and sporadic
presentation (n = 81) were invited to genetic screening; 71
patients accepted. Germline mutations were investigated by
using direct sequencing for point mutations in RET, SDHB,
SDHD, and VHL, and multiplex ligation-dependent probe
ampliﬁcation for gross deletions in SDHB, SDHC, SDHD,
and VHL. Plasma or urinary metanephrines and/or urinary
catecholamines were used for biochemical follow-up.
Results The prevalence of germline mutations was 5.6%.
Mutations were only seen in RET (n = 1) and SDHB
(n = 3). Notably, in the patients with SDHB mutations, no
malignant phenotype was observed during a mean follow-
up of 23.3 years.
Conclusions The frequency of germline mutations in
patients with apparently sporadic Pheo and abdominal PGL
in Western Sweden was lower than in previous studies.
Variations in reported frequencies of germline mutations in
patients with clinically sporadic Pheo/PGL may reﬂect
geographical differences or patient selection.
Introduction
The list of known genes causing hereditary pheochromo-
cytoma (Pheo) or paraganglioma (PGL) is expanding and
includes NF1 in neuroﬁbromatosis type 1 (NF1), RET in
multiple endocrine neoplasia syndrome type 2 (MEN2),
VHL in Von Hippel–Lindau syndrome (VHL), succinate
dehydrogenase subunit genes SDHB, SDHC, and SDHD
and the succinate dehydrogenase complex assembly factor
2 gene SDHAF2 in familial paraganglioma syndromes
PGL4, PGL3, PGL1, and PGL2, respectively. Recently
mutations in PHD2 [1], SDHA [2], TMEM127 [3], Kif-1Bb
[4], and MAX [5] have been described in association with
Pheo/PGL. Since Neumann et al. [6] in 2002 reported 24%
germline mutations in SDHB, SDHD, RET, and VHL in
patients with clinically nonsyndromic Pheo/PGL, genetic
screening in these patients has attracted considerable
interest. An algorithm for testing based on clinical risk
factors (family history or age \35 years, extra-adrenal,
bilateral or malignant tumours) was published in 2006 [7],
Preliminary reports of this work have been presented at the 2nd
International Symposium on Pheochromocytoma, 2008, Cambridge,
UK, and at the MEN2010 meeting, September 2010, Gubbio, Italy.
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[8–10]. In cohorts with Pheo/PGL and sporadic presenta-
tion published after 2002, the frequency of germline
mutations have ranged from 7.5 to 19.1% [8–12]. The wide
variation may represent geographical differences and/or
patient selection, and population-based studies are needed.
To establish population-based data on the frequency of
germline mutations in patients with apparently sporadic
Pheo or abdominal PGL in Western Sweden, we have
offered genetic screening to all living patients from our
region registered in the National Cancer Registry (NCR)
from 1958 to 2009.
Patients and methods
Setting
The western healthcare region in Sweden comprises the
region of Va ¨stra Go ¨taland and the municipalities Varberg,
Falkenberg, and Kungsbacka, with a total population (June
2008) of 1.72 million inhabitants.
Data sources
National Cancer Registry
Mandatory reporting of Pheo and PGL to the NCR started
in 1958. The reporting frequency is high; approximately
96% of cases were reported to the NCR according to a
recent survey [13]. From the NCR, all patients in the
western healthcare region with a diagnosis of Pheo or PGL
were identiﬁed. Search terms were: ICD-7 localization
codes 195.0 (adrenal medulla) and 195.7 (paraganglia);
morphology codes 441 (benign Pheo/PGL) and 446
(malignant Pheo/PGL or malignant neuroendocrine tumor).
Only patients with histopathologically veriﬁed disease
were included.
Hospital records and clinical interviews
From register data, hospital records and clinical interviews
information on diagnosis, age at diagnosis, presentation
(sporadic or hereditary/syndromic), tumor location and
secretory proﬁle, and metastatic or recurrent disease was
collected. Sporadic presentation was deﬁned as a negative
family history and absence of syndromic lesions associated
with MEN2, NF1, or VHL at diagnosis. Malignancy was
deﬁned as presence of metastases at the time of diagnosis
or during follow-up. To distinguish metastatic from mul-
tifocal disease, a diagnosis of metastatic disease required
that chromafﬁn tissue was present at a site where chro-
mafﬁn tissue is not otherwise found [14]. Because criteria
for malignancy in Pheo and PGL have changed over time,
histopathological reports were reviewed and in selected
cases specimens were reanalyzed to update diagnoses to
the current deﬁnitions. Plasma or urinary metanephrines
and/or urinary catecholamines were used for biochemical
follow-up.
Eligibility criteria
All patients with Pheo or abdominal PGL and sporadic
presentation were invited to genetic screening, which
started in spring 2006. All participating patients gave oral/
written consent. The study was approved by the Regional
Ethical Review Board in Gothenburg (registration number
652-06).
Genetic screening
Based on the presumed frequency of ﬁndings stepwise
genetic testing was performed in the following order: (1)
Sanger sequencing for point mutations in SDHB (exon
1–8), SDHD (exon 1–4) and VHL (exon 1–3); (2) In
patients with negative sequencing results in SDHB, SDHD,
and VHL sequencing of RET (exons 10, 11, 14, and 16); (3)
In patients negative after testing for RET-mutation the
presence of deletions in SDHB, SDHC, SDHD, and VHL
was investigated by using multiplex ligation-dependent
probe ampliﬁcation (MLPA).
DNA sequencing
DNA was enriched from blood by the DNeasy kit from
Qiagen (Qiagen, Hilden, Germany) using the Hamilton
ML-Star pipetting robot (Hamilton, www.hamiltonrobotics.
com/).
The primers, covering coding regions in RET gene
(Accession number: NM_020975) exon 10, 11, 14, and 16
and all coding regions of the VHL (Accession number:
L15409), SDHB (Accession number: NM_003000), and
SDHD (Accession number: NM_003002) genes were
designed using ExonPrimer (http://ihg.gsf.de/ihg/Exon
Primer.html) or Primer Express
 Software v2.0 (Applied
Biosystems), and PCR reactions were set up using the
automated workstation Biomek
 FX (Beckman Coulter,
www.beckmancoulter.com) and performed in 10-ll reac-
tions according to standard procedures. PCR products for
VHL, SDHB, and SDHD were cleaned using magnetic
beads (AMPure, Agencourt, Bioscience Corporation,
Beverly, MA) and for RET using the Qiagen MinElute PCR
Puriﬁcation kit (Qiagen), and sequenced using BigDye

Terminator v 3.1 Cycle Sequence Kit (Applied Biosys-
tems) in 10-ll reactions according to manufacturer’s pro-
tocol. The sequence PCR thermal proﬁle for GC-rich
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123fragments (e.g., VHL exon 1) were modiﬁed to longer
denaturation steps and increased number of cycles (i.e., 50
cycles). The sequence-PCR products were cleaned using
magnetic beads (CleanSeq, Agencourt) and separated by
gel electrophoresis on a 3730 DNA Analyzer (Applied
Biosystems). Results were analysed using Sequencing
Analysis v. 5.2 and SeqScape v.2.5 (Applied Biosystems).
MLPA—SDHB, SDHC, SDHD, and VHL
DNA enriched from blood (cf. DNA sequencing—SDHB,
SDHD, and VHL section) was analyzed for exon deletions
by MLPA for SDHB, SDHC, and SDHD (SALSA P226,
MRC Holland, Amsterdam, The Netherlands) and VHL
(SALSA P016-B2) and run according to the manufac-
turer’s recommendations. Results were analyzed using the
GeneMapper v.3.7 software (Applied Biosystems), and
normalization was performed in R 2.9.2. For each case, the
MLPA peak heights and peak areas were compared to three
independent controls from Western Sweden.
Results
From 1958 to 2009, 256 patients with Pheo or PGL were
registered in the NCR (Fig. 1). Of these, 127 had Pheo or
abdominal PGL with sporadic presentation (mean age
52.5 years; 54% women). Twenty-four patients had
hereditary or syndromic presentation (MEN2 n = 13, NF1
n = 9, VHL n = 1, Carney syndrome n = 1), 20 had
extra-abdominal paragangliomas, and 1 patient with pri-
mary hyperparathyroidism was misclassiﬁed in the
All patients with Pheo/PGL in the western health-
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aMean age at diagnosis.
bThe
son of one of the patients had an
SDHB mutation (c.418G[T) but
no evidence of disease; the
mutation status of the deceased
father is unknown
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123registry. Information on presentation was missing in 28
deceased patients (Pheo n = 6, PGL n = 10, malignant
Pheo n = 9, malignant PGL n = 3; mean age 59.2 years,
mean time from diagnosis to death 7.6 years). Fifty-six
patients were diagnosed postmortem (Pheo n = 39, PGL
n = 5, malignant Pheo n = 12).
Of the 127 patients with sporadic presentation, 81 were
alive and were invited to the study, and 71 (88%) gave their
consent and underwent testing. Forty-six of the 127
patients were dead; the mean survival time from diagnosis
was 12 years. Patient characteristics are shown in Fig. 1.
Sequencing revealed one case with a missense mutation in
the RET-gene, two cases with missense, and one case with a
splice-site mutation inSDHB(Table 1). Sixpatientshad single
nucleotide polymorphisms in SDHB:c . 1 8 A [C (p.Ala6Ala)
n = 4; c.24C[T (p.Ser8Ser) n = 1; c.487T[C (p.Ser163Pro)
n = 1, Leiden Open Variants Database (LOVD) ID
SDHB_00008,SDHB_00011,andSDHB_00038,respectively
(http://chromium.liacs.nl/lovd_sdh/home.php?select_db=SDHB)
[15]. No mutations were found in SDHD or VHL. No dele-
tions or rearrangements were found by MLPA analysis.
The patient with a previously unrecognized RET
p.Cys609Tyr mutation underwent a prophylactic thyroid-
ectomy at age 40 years, 13 years after surgery for Pheo. At
that time, she had no signs of recurrence of Pheo. On
histopathological analysis, no C cell hyperplasia or med-
ullary thyroid carcinoma was found. All three patients with
SDHB mutations are alive without evidence of tumor
recurrence or malignant development at 15.7, 26.0, and
28.1 years of follow-up, respectively (Table 1).
Discussion
In this population-based study of patients with Pheo or
abdominal PGL with sporadic presentation registered in the
National Cancer Registry for Western Sweden 1958–2009,
the prevalence of germline mutations was 5.6%. Mutations
were only seen in RET and SDHB. Notably, in the patients
with SDHB mutations no evidence of malignancy was
observed during a mean follow up of 23.3 years.
Differences in the reported frequency of germline
mutations may reﬂect genetic differences in different
populations/geographical areas and/or differences in
patient selection. In the present study, 82% had isolated
apparently sporadic single Pheo. Cascon et al. [10] reported
9% germline mutations in patients with a single Pheo/PGL
and sporadic presentation, and only 2.3% in patients with a
single apparently sporadic Pheo. In the present study, the
susceptibility genes RET, SDHB, SDHD, and VHL were
sequenced, and deletions were excluded in SDHB, SDHC,
and SDHD-genes and VHL. The mutation detection meth-
ods used in this study are well-established techniques and
have been used by other investigators in this context [9].
Whereas Sanger sequencing shows a [99.6% sensitivity
for unidirectional analysis of heterozygous base substitu-
tions [16], the MLPA technique is reported to show a
sensitivity of approximately 92% [17]. The genetic testing
methodology used is therefore not likely to explain the low
prevalence of mutations found in this study. SDHC-muta-
tion in apparently sporadic abdominal PGL seems rare
[18].
Considering established risk factors for hereditary dis-
ease [7], tested patients were more likely to have germline
mutations than patients who did not consent to the study
and patients who had died before the study started, because
tested patients were younger and more frequently had
malignant disease. Still, a signiﬁcant number of patients in
the total cohort were deceased and a higher mutation fre-
quency among these cannot be excluded. No systematic
screening of relatives of living or deceased patients has yet
been performed. However, a 39-year-old son of one
deceased man with a malignant PGL has been diagnosed
with an SDHB mutation (418 G[T, p.Val140Phe, LOVD








Secr Mutation LOVD ID
c FU (years) Status
c.DNA Protein
25, F Pheo No E SDHB c.716C[G p.Ser239Cys Submitted 26.0 NED
49, M Pheo No NE SDHB c.725G[A p.Arg242His SDHB_00004 15.7 NED
15, F PGL No NE SDHB c.IVS4?1G[A Splice-site SDHB_00047 28.1 NED
27, F Pheo No E RET c.1826G[A p.Cys609Tyr – 13 NED
Pheo pheochromocytoma, PGL paraganglioma, Secr secretory pattern, E epinephrine, NE norepinephrine, FU follow-up, NED no evidence of
disease
a Age at diagnosis
b Malignant (metastases at presentation or during follow-up), bilateral or multifocal tumor
c Leiden Open Variation Database (http://chromium.liacs.nl/lovd_sdh/home.php?select_db=SDHB)
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123ID SDHB_00095). He has no evidence of disease. The
mutation status of the father is unknown (Fig. 1).
Hereditary tumors occur at a younger age than sporadic
tumors. Age\35 years at presentation is a risk factor for
hereditary disease [7]. In this study, tested patients aged
\35 years at presentation had a mutation frequency of
17.6%, compared to 1.9% in patients aged [35 years
(Fig. 1; Table 1). It should be noted that three of four
patients with germline mutations in the present study were
younger than 30 years at presentation. In series of patients
\20 years, one-third may be mutation carriers [9, 19].
SDHB carriers develop a malignant phenotype in
34.3–37.5% of the cases [20, 21]. In the present study, no
patient with SDHB mutation had developed malignancy
at presentation or during long-time follow-up (mean
23.3 years). Hypermethylation of the P16
INK4A promotor
has been associated with malignant phenotype in SDHB
carriers [22], indicating stepwise genetic changes during
the malignant transformation. To better tailor the follow-up
of SDHB carriers, more information is needed on the
impact of speciﬁc mutations and also how epigenetic
alterations inﬂuence the phenotype.
Genetic analyses are time-consuming and costly. To
minimize the number of analyses, most authors suggest a
stepwise testing based on clinical data [8–10]. To speed up
the process and cut costs, immunohistochemical analysis of
SDHB protein expression in tumor tissue [23] has been
used as a highly sensitive and speciﬁc screening tool to
discriminate SDH-related from non-SDH-related tumours.
Denaturing high performance liquid chromatography also
has been used as a fast and relatively inexpensive screening
method [24].
In this registry-based study, we found a frequency of
germline mutations in patients with apparently sporadic
pheochromocytoma and abdominal paraganglioma in
Western Sweden of 5.6%. Differences in reported fre-
quencies of germline mutations in patients with clinically
sporadic Pheo/PGL may reﬂect geographical differences or
patient selection.
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